Clinical trial

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

NCT07158489

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-08-21

PhasePHASE2

Study timeline

Study start (actual)2026-08-21Date precision: day

Registry last updated2026-08-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLCunresolved

NSCLC (Advanced Non-small Cell Lung Cancer)unresolved

Interventions

Gemcitabine + IvonescimabDRUG

Sponsors & collaborators

Swiss Cancer Institutelead sponsor

Mapped research locations

BaselSwitzerland1 GenevaSwitzerland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07158489 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.